CareDx, Inc. - Common Stock (NQ:CDNA)

86.68 +15.16 (+21.20%)

Delayed Quote Updated: 9:39 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

February 03, 2026

From CareDx, Inc.

Via Business Wire

CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026 ↗

February 01, 2026

The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.

Via The Motley Fool

Topics Regulatory Compliance

CareDx President and CEO Sells 19,000 Shares for $412,000 ↗

January 30, 2026

This transplant diagnostics specialist saw a notable insider sale amid a year of modest share price decline and ongoing product innovation.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

4 Analysts Assess CareDx: What You Need To Know ↗

September 23, 2025

Via Benzinga

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 27, 2026

From CareDx, Inc.

Via Business Wire

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 12, 2026

From CareDx, Inc.

Via Business Wire

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

January 07, 2026

From CareDx, Inc.

Via Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 26, 2025

From CareDx, Inc.

Via Business Wire

CareDx Provides Notice of Proposed Derivative Settlement

December 18, 2025

From CareDx, Inc.

Via Business Wire

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

November 24, 2025

From CareDx, Inc.

Via Business Wire

CareDx to Participate in Upcoming Investor Conferences

November 10, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

November 06, 2025

From CareDx, Inc.

Via Business Wire

3 Analysts Have This To Say About CareDx ↗

November 06, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

What's going on in today's after hours session ↗

November 04, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

CareDx Announces Third Quarter 2025 Financial Results

November 04, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

October 27, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

October 23, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

October 22, 2025

From CareDx, Inc.

Via Business Wire

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

October 21, 2025

From CareDx, Inc.

Via Business Wire

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

October 06, 2025

From CareDx, Inc.

Via Business Wire

CareDx Issues Comment Letter on Draft LCD Policy

September 02, 2025

From CareDx, Inc.

Via Business Wire

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential ↗

August 26, 2025

CareDx, Inc. faces uncertainty with proposed reimbursement changes, but has long-term potential in the $8 billion transplant solutions market.

Via Benzinga

This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗

August 26, 2025

Via Benzinga

CareDx to Participate in Wells Fargo Healthcare Conference

August 21, 2025

From CareDx, Inc.

Via Business Wire

CareDx (CDNA) EPS Beats Sales Gain 14% ↗

August 06, 2025

Via The Motley Fool

CareDx Inc (NASDAQ:CDNA) Posts Mixed Q2 2025 Results Amid Revenue Adjustments and Testing Growth ↗

August 06, 2025

CareDx Inc (CDNA) reported mixed Q2 2025 results with revenue of $86.7M, missing estimates, but adjusted revenue rose 14% YoY. Testing volumes grew 13%, while shares fell 6.8% post-earnings.

Via Chartmill

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

August 06, 2025

From CareDx, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.